Quintiles' banner business came up short in the first quarter, as currency fluctuations bit into revenue and led the world's largest CRO to dial down its full-year guidance.
PPD and partner Shin Nippon Biomedical Laboratories (SNBL) have hit the ground running with their Japanese joint venture, closing a deal that will see them join forces in the country's growing market for clinical trials. Read more >>
WuXi PharmaTech, China's largest CRO, is positioning itself to cash in on the fervor over new immunotherapies for cancer, planning to build a U.S. facility devoted to manufacturing the newfangled cell therapies. Read more >>
POPULAR COMMENT THREADS
WuXi PharmaTech's CEO has teamed up with a major investor in an attempt to take the CRO private, pitching a buyout that would give the Chinese company's shareholders a 16.2% premium.
A group of Quintiles shareholders including the CRO's founder made about $770 million in a secondary stock offering, selling a bulk of shares back to the company and cashing in on its success.
A year removed from taking a private equity buyout, U.K. CRO Quotient Clinical has watched demand for its services spike, the company said, plotting some major investments to keep the pace of growth.
CRO inVentiv Health is amping up its capacity in regulatory compliance to prepare for changes in European trial rules, unveiling a global database it claims can help sponsors avoid costly confusion.
WuXi PharmaTech, China's largest CRO, again boosted its revenue by double digits last quarter, keeping the pace of growth as it considers an offer to go private.
Contract drug developer Patheon has flipped its Mexican operations to Perrigo for $34 million in cash, shifting its focus to the U.S. and Europe.
From Our Sister Sites
In this week's EuroBiotech Report, Abivax became the latest French biotech to file for an IPO in its home country, seeking cash ahead of moving an HIV drug into two Phase IIb trials, as well as to support the clinical development of its lead candidate, a therapeutic vaccine against hepatitis B. And more.
The antibody experts at arGEN-X have teamed up with dermatology-focused biotech Leo Pharma on a treatment for inflammatory skin diseases, inking a deal worth up to $116 million.